ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$312.01
-4.00 (-1.27%)
▼
5d:
-4.26%
30d:
+4.82%
90d:
+6.18%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 4.5% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 4.5% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$471.37
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$292.68
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $312.01, which is considered fair relative to its 30-day fair value range of $293.75 to $323.08. From a valuation perspective, the stock is trading at a discount (Forward PE: 32.6) compared to its historical average (37.5). Remarkably, the market is currently pricing in an annual earnings decline of 4.5% over the next few years. This pessimistic expectation contrasts with the company's recent 16970.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is showing sideways momentum. The price is currently testing key support at $309.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $415.64 (+31.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ONC is showing sideways momentum. The price is currently testing key support at $309.94. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $415.64 (+31.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$293.75 -
$323.08
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.5% below Wall St target ($415.64)
Trading Range Analysis
30-Day Trading Range
$293.75 -
$323.08
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$309.94
Resistance Level
$331.69
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
32.64
Wall Street Target
$415.64
(+31.5%)
Revenue Growth (YoY)
35.5%
Earnings Growth (YoY)
16970.8%
Profit Margin
8.9%
Valuation Discount vs History
-4.5% cheaper
PE vs Historical
32.6 vs 37.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.5%
(market-implied from PE analysis)
1-Year Target
$301.79
(-5%)
2-Year Target
$288.21
(-9%)
3-Year Target
$275.24
(-13%)
3-Yr Target (if PE normalizes)
(PE: 33→38)
$316.24
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 32.6, Growth: 47.8%)
$1020.66
(+223%)
Base:
(SPY PE: 20.7, Growth: 47.8%)
$648.26
(+105%)
Bear:
(PE: 17.6, Growth: 47.8%)
$551.02
(+74%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (50x PE), but valuation improves significantly next year (33x PE) as earnings recover.
Forward PE: 49.75 | Forward EPS (Implied): $6.35
Bull Case
$381.58
(+21%)
Analyst growth 15.0%, PE expands to 52.2
Base Case
$316.01
(0%)
Market implied 0.0%, PE stable at 49.8
Bear Case
$241.75
(-24%)
Severe decline -15.0%, PE contracts to 44.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 32.6 to 37.5
Stabilization Target:
$363.08
(+14.9%)
PE Expansion Potential:
+14.9%
Share & Embed Analysis
Last updated: August 03, 2026 3:19 PM ET
Data refreshes hourly during market hours. Next update: 4:19 PM
Data refreshes hourly during market hours. Next update: 4:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Chan Henry Lee
SELL
341 shares
2026-03-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |